Blepharitis

Latest News

Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point - Image credit: ©patpitchaya—stock.adobe.com
Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point

July 23rd 2025

The solution missed the primary end point of the trial, which was complete resolution of debris after 6 weeks of twice-daily dosing.

Image Credit: © ohishift - stock.adobe.com
Safety, efficacy of lotilaner ophthalmic solution for Demodex blepharitis treatment

March 31st 2023

SECO 2023: Drugs of the future
SECO 2023: Drugs of the future

March 2nd 2023

Eye care therapies on the move: What’s in the pipeline
Eye care therapies on the move: What’s in the pipeline

September 16th 2022

Effective treatments for presbyopia, myopia, demodex
Effective treatments for presbyopia, myopia, demodex

March 12th 2022

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.